A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
ApexOnco Front Page
Recent articles
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
Readout of the Pivot-006 trial is brought forward by nearly a year.
$650m buys the group rights to RemeGen’s RC148.
After Aktis's $318m flotation Eikon is a bigger proposition.
